(Q34620975)

3 August 2017

title

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients (English)

1 reference

chronic lymphocytic leukemia

3 August 2017

0 references

1 reference

1 reference

1 reference

17

Giovanni Martinelli

1 reference

3 August 2017

Paola Bertazzoni

1

1 reference

3 August 2017

Cristina Rabascio

2

1 reference

3 August 2017

Federica Gigli

3

1 reference

3 August 2017

Liliana Calabrese

4

1 reference

3 August 2017

Davide Radice

5

1 reference

3 August 2017

Angelica Calleri

6

1 reference

3 August 2017

Giuliana Gregato

7

1 reference

3 August 2017

Mara Negri

8

1 reference

3 August 2017

Sarah J Liptrott

9

1 reference

3 August 2017

Simona Bassi

10

1 reference

3 August 2017

Luca Nassi

11

1 reference

3 August 2017

Simona Sammassimo

12

1 reference

3 August 2017

Daniele Laszlo

13

1 reference

3 August 2017

Lorenzo Preda

14

1 reference

3 August 2017

Giancarlo Pruneri

15

1 reference

3 August 2017

Laura Orlando

16

1 reference

3 August 2017

publication date

1 August 2010

1 reference

3 August 2017

1 reference

3 August 2017

volume

51

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1485-1493

1 reference

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Real time quantitative PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.495799

10.3109/10428194.2010.495799

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference